<unk>  is a combination of an HIV-1 integrase strand transfer inhibitor, a CYP3A inhibitor, and two HIV-1 nucleoside analog reverse transcriptase inhibitors that is FDA approved for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of<unk> . There is a Black Box Warning for this drug as shown here.  Common adverse reactions include nausea and decreased bone mineral density.
Elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide
Dolutegravir / rilpivirine
Atazanavir and cobicistat
Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate
Efavirenz, emtricitabine and tenofovir disoproxil fumarate
Bictegravir / emtricitabine / tenofovir alafenamide
Emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide fumarate
Darunavir ethanolate and cobicistat